Edition:
United States

Vertex Pharmaceuticals Inc (VRTX.OQ)

VRTX.OQ on NASDAQ Stock Exchange Global Select Market

158.69USD
23 Apr 2018
Change (% chg)

$0.54 (+0.34%)
Prev Close
$158.15
Open
$158.71
Day's High
$160.09
Day's Low
$157.74
Volume
382,878
Avg. Vol
618,243
52-wk High
$178.17
52-wk Low
$113.66

Select another date:

Tue, Apr 17 2018

BRIEF-Vertex Pharma CEO's FY 2017 Total Compensation $17.3 Mln

* VERTEX PHARMACEUTICALS INC SAYS CEO JEFFREY LEIDEN'S FY 2017 TOTAL COMPENSATION WAS $17.3 MILLION VERSUS $17.4 MILLION IN FY 2016 - SEC FILING Source text (https://bit.ly/2JVKbq6) Further company coverage:

BRIEF-Veritas Pharma Enters Into Share Purchase Agreement With 3 Carbon Extractions Inc.

* VERITAS PHARMA ENTERS INTO SHARE PURCHASE AGREEMENT WITH 3 CARBON EXTRACTIONS INC. Source text for Eikon: Further company coverage: (Reuters.Briefs@thomsonreuters.com)

BRIEF-Vertex Pharmaceuticals CEO Leiden's 2017 Compensation Was $17.2 Mln

* VERTEX PHARMACEUTICALS INC - CEO JEFFREY LEIDEN'S 2017 TOTAL COMPENSATION WAS $17.2 MLN VS $17.4 MLN IN 2016 - SEC FILING Source text - https://bit.ly/2uQs5Cx Further company coverage:

BRIEF-Q-State Biosciences Says Entered Strategic Collaboration With Vertex Pharmaceuticals

* PER TERMS OF DEAL, CO TO RECEIVE UPFRONT & RESEARCH SUPPORT, ELIGIBLE TO RECEIVE RESEARCH, DEVELOPMENT & SALES MILESTONES

BRIEF-Vertex Appoints Reshma Kewalramani As Chief Medical Officer

* VERTEX APPOINTS RESHMA KEWALRAMANI, M.D., AS CHIEF MEDICAL OFFICER Source text for Eikon: Further company coverage:

BRIEF-Vertex Initiates Late Stage Study Of Treatment Combination For Cystic Fibrosis

* VERTEX INITIATES FIRST PHASE 3 STUDY OF VX-659, TEZACAFTOR AND IVACAFTOR AS A TRIPLE COMBINATION REGIMEN FOR PEOPLE WITH CYSTIC FIBROSIS

BRIEF-Vertex Says Mid Stage Study Testing Pain Relief Drug Met Main Goal

* VERTEX ANNOUNCES TREATMENT WITH THE NAV1.8 INHIBITOR VX-150 SHOWED SIGNIFICANT RELIEF OF ACUTE PAIN IN PHASE 2 STUDY

UPDATE 1-U.S. FDA approves Vertex cystic fibrosis combination treatment

Feb 12 The U.S. Food and Drug administration on Monday approved a treatment for cystic fibrosis that combines Vertex Pharmaceuticals Inc's Kalydeco with another medicine, Vertex said, marking the company's third product for the life-shortening lung disorder.

U.S. FDA approves Vertex cystic fibrosis combination treatment

Feb 12 The U.S. Food and Drug administration on Monday approved a treatment for cystic fibrosis that combines Vertex Pharmaceuticals Inc's Kalydeco with another medicine, Vertex said, marking the company's third product for the life-shortening lung disorder.

BRIEF-Vertex Pharma Says Established Wholesale Acquisition Cost Of $292,000 For SYMDEKO In U.S. On Annual Basis

* VERTEX PHARMA - HAVE ESTABLISHED WHOLESALE ACQUISITION COST FOR SYMDEKO IN UNITED STATES OF $292,000 ON ANNUAL BASIS ($22,400 PER 28-DAY PACK)

Select another date: